Patrick Wood

“First one around Voyager, how you guys are feeling about things are going there, you know, how it fits into glaucoma treatment and how that's gone recently.”

“The first one on the Smith & Nephew partnership, how did that come about? How are you thinking about the potential contribution for that? And did we factor any that into the guide?”

“I guess the first one, just big picture, when we're looking forward into 26 and the growth guide that we have, how are you guys thinking about the composition of that?”

“First one, I know you guys don't guide to it, but just a sense of OUS, I understand why we've all been focused obviously on the U.S. at the moment, but the relative guide going forward in the sense of the contribution 26 that you guys expect from OUS would be Thank you.”

“I'd love to just ask a slightly boring one, but on pricing, moving to a negative 100 base points of erosion in the 26 guide, You know, inflation is kind of at the same spot that it was before, and I'm guessing your customers are in a pretty healthy spot from procedure volumes.”